GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
SOMERVILLE, Mass. and PARIS, August 24, 2022 /PRNewswire/ — GNSthe leader in the use of “digital twins” and causal AI and biosimulation technology for biopharmaceutical drug discovery and development, and servanta global pharmaceutical company, today announced a collaboration to advance drug discovery, translation and clinical development efforts in multiple myeloma (MM).
“This collaboration continues Servier’s goal of accelerating its drug discovery and clinical development efforts through AI, biosimulation and other digital initiatives,” said Claude-Bertrand, EVP Research and Development at Servier. “We believe that the GNS Double digital and unique causal AI models will help our research and early development group improve our understanding of MM disease biology and ultimately transform our drug discovery and clinical development process.”
“We are excited to collaborate with Servier to help advance MM research and leverage our Gemini Digital Twin models to help uncover new insights and reveal the hidden biological circuits of this disease,” said Joe Donahue, commercial director at GNS. “By working with the exceptional team at Servier, we hope to make a difference in the lives of MM patients.”
The collaboration will address key questions about the progression of MM in different patient subpopulations, including uncovering which are the most synergistic pathways for novel combination therapies and will help Servier gain insights that can advance its translational development efforts and clinical. This work will initially rely on the GNS Gemini digital twin for MM developed using rich clinico-genomic data from the Multiple Myeloma Research Foundation (MMRF) CoMMpass study.
GNS’ MM Digital Twin leverages the rich multimodal patient data generated by MMRF to create a transparent, accurate, and quantified representation of complex biological mechanisms, revealing new human disease circuits. By conducting biosimulations, which are essentially computational experiments, one can discover new drug targets and disease mechanisms, and one can also determine which drug candidates are more effective than others and why certain patient molecular profiles lead to a better and longer lasting response. Ultimately, MM digital twins will radically change the way pharmaceutical R&D is conducted by helping to accelerate the identification of new targets and target combinations, new biomarkers, and enabling the silicone design of better trials.
About Servier Group
Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total turnover of €4.7 billion in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests more than 20% of its brands’ turnover in Research and Development each year. To accelerate therapeutic innovation in the service of patients, the Group engages in open and collaborative innovation with academic partners, pharmaceutical groups and biotechnology companies. It also integrates the voice of the patient at the heart of its activities.
A leader in cardiology, the Groupe Servier’s ambition is to become a recognized and innovative player in oncology. Its growth is based on a sustained commitment in cardiovascular and metabolic diseases, oncology, neurosciences and immuno-inflammatory diseases. To promote access to care for all, the Servier group also offers a range of quality generic drugs covering most pathologies.
GNS is the leader in applying causal AI and simulation technology to discover and validate new drug targets, simulate clinical trials, and help pharmaceutical and biotechnology companies discover and develop new drugs faster. GNS’ patented AI unlocks new insights from multi-omics and real-world data leading to the discovery and prioritization of novel biological targets, and more efficient clinical trials with patients likely to respond to therapies. Gemini Digital Twin models for oncology, autoimmune diseases, and neurology allow simulation of disease progression and drug response at the individual patient level to simulate clinical trials in diverse patient cohorts. GNS partners include seven of the top ten pharmaceutical companies, leading research centers, medical companies and patient advocacy groups worldwide. Our advisory board is made up of a renowned group of scientific and medical experts.
Servier Group (
France And in the world)
+33 (0)1 55 72 40 21